We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This report presents the findings of an evaluation of the programme, which provided a combination of Individual Placement Support (IPS) and Improving Access to Psychological Therapies (IAPT).
Following a 2025 government commission, the ACMD has carried out a review of the use and harms of ketamine.
Tracking public attitudes to and awareness of transport technologies in the UK.
Survey of adults and children in private households, reporting prevalence of health related behaviours and health status and conditions.
KPI (Key Performance Stats) data for antenatal and newborn and young person and adult screening relating to Quarter 4 (1 January to 31 March 2024)
KPI (Key Performance Stats) data for antenatal and newborn and young person and adult screening relating to April 2023 to March 2024
KPI (Key Performance Stats) data for antenatal and newborn and young person and adult screening relating to Quarter 3 (1 October to 31 December 2023)
KPI (Key Performance Stats) data for antenatal and newborn and young person and adult screening relating to April 2022 to March 2023
KPI (Key Performance Stats) data for antenatal and newborn and young person and adult screening relating to Quarter 2 (1 July to 30 September 2023)
KPI (Key Performance Stats) data for antenatal and newborn and young person and adult screening relating to Quarter 1 (1 April 2022 - 30 June 2022)
KPI (Key Performance Stats) data for antenatal and newborn and young person and adult screening relating to Quarter 1 (1 April 2023 - 30 June 2023)
KPI (Key Performance Stats) data for antenatal and newborn and young person and adult screening relating to Quarter 4 (1 January 2023 - 31 March 2023)
KPI (Key Performance Stats) data for antenatal and newborn and young person and adult screening relating to Quarter 3 (1 October 2022 - 31 December 2022)
Key Performance Indicator (KPI) data for antenatal and newborn and young person and adult screening relating to quarter 2 (1 July to 30 Sept 2024)
Key Performance Indicator (KPI) data for antenatal and newborn and young person and adult screening relating to quarter 3 (1 Oct to 31 Dec 2024)
Key Performance Indicator (KPI) data for antenatal and newborn and young person and adult screening relating to quarter 1 (1 April to 30 June 2024)
Key Performance Indicator (KPI) data for antenatal and newborn and young person and adult screening relating to quarter 4 (1 Jan to 31 Mar 2025)
KPI (Key Performance Indicator) data for antenatal and newborn and young person and adult screening relating to Quarter 2 (1 July 2022 - 30 September 2022)
Tables showing deaths registered in Northern Ireland in 2026, up to and including 16 January 2026.
Report of the Isotretinoin Implementation Advisory Expert Working Group regarding recommendations to strengthen the safe use of isotretinoin, the acne medicine commonly known by brand names Roaccutane and Reticutan.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).